Aurinia Pharmaceuticals Signs Agreement To Acquire Kezar Life Sciences For $6.955/Share In Cash

Aurinia Pharmaceuticals Inc. has signed a definitive merger agreement to acquire Kezar Life Sciences for $6.955 per share in cash. The deal includes a non-transferable contingent value right (CVR) that could provide additional payments related to ongoing clinical developments and collaborations. Kezar Life Sciences focuses on small-molecule therapeutics for autoimmunity and cancer, and the acquisition aims to enhance Aurinia's portfolio in these areas.